“This trial will be conducted under the same FDA-approved IND as the Company’s recently initiated Phase 2 clinical trial to treat COVID-19 patients with mild-to-moderate indications.”

Doesn’t this mean they can immediately inject patients in the severely ill protocol?

“CytoDyn expects to enroll patients in both the Mild-to-Moderately Ill and Severely Ill protocols very quickly under the same IND that was provided with a “safe to proceed” letter from the FDA.”